Medications development to treat alcohol dependence: a vision for the next decade - PubMed (original) (raw)

Review

Medications development to treat alcohol dependence: a vision for the next decade

Raye Z Litten et al. Addict Biol. 2012 May.

Abstract

More than 76 million people world-wide are estimated to have diagnosable alcohol use disorders (AUDs) (alcohol abuse or dependence), making these disorders a major global health problem. Pharmacotherapy offers promising means for treating AUDs, and significant progress has been made in the past 20 years. The US Food and Drug Administration approved three of the four medications for alcoholism in the last two decades. Unfortunately, these medications do not work for everyone, prompting the need for a personalized approach to optimize clinical benefit or more efficacious medications that can treat a wider range of patients, or both. To promote global health, the potential reorganization of the National Institutes of Health (NIH) must continue to support the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) vision of ensuring the development and delivery of new and more efficacious medications to treat AUDs in the coming decade. To achieve this objective, the NIAAA Medications Development Team has identified three fundamental long-range goals: (1) to make the drug development process more efficient; (2) to identify more efficacious medications, personalize treatment approaches, or both; and (3) to facilitate the implementation and adaptation of medications in real-world treatment settings. These goals will be carried out through seven key objectives. This paper describes those objectives in terms of rationale and strategy. Successful implementation of these objectives will result in the development of more efficacious and safe medications, provide a greater selection of therapy options and ultimately lessen the impact of this devastating disorder.

Published 2012. This article is a U.S. Government work and is in the public domain in the USA.

PubMed Disclaimer

Conflict of interest statement

Disclosure/Conflict of Interest

The authors declare that, except for M.R. who is a government contractor and has received income from Merck for support of one of their trials, they have not received compensation from any individual or corporate entity over the past 3 years for research or professional service. In addition, there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.

Figures

Figure 1

Figure 1

Phases of Alcohol and Drug Development

Similar articles

Cited by

References

    1. Agres T, Gwynne P. Scientific American Pathways: 2010. New York: Scientific American; 2010. Remodeling pharma; pp. 66–76.
    1. Anton RF, Litten RZ, Falk DE, Palumbo JM, Bartus RT, Robinson RL, Kranzler HR, Kosten TR, Meyer RE, O’Brien CP, Mann K, Meulien D. The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and goals for assessing important and salient issues for medications development alcohol use disorders. Neuropsychopharmacology. 2011 (online) - PMC - PubMed
    1. Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Jian Han. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psycholpharmacol. 2008;28:5–12. - PubMed
    1. Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence. JAMA. 2006;295:2003–2017. - PubMed
    1. Anton RF, Drobes DJ, Voronin K, Duraxo-Avizu R, Moak D. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology. 2004;173:32–40. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources